Kedrion Biopharma
Fabrizio Taglieri has a strong background in manufacturing science and development within the biopharmaceutical industry. Fabrizio has held various leadership roles at companies like Kedrion Biopharma, Takeda, Shire, Baxalta, and Baxter International Inc. Fabrizio'sexperience includes overseeing global manufacturing processes, managing teams focused on process improvements, and ensuring quality and efficiency across multiple manufacturing sites. Throughout their career, Fabrizio has demonstrated expertise in new product development, process harmonization, and business management within the pharmaceutical sector.
Fabrizio Taglieri completed their degree in Chemistry and Pharmaceutical Technologies at Sapienza Università di Roma's Pharmacy Faculty from 2000 to 2008. Fabrizio also obtained certifications in Leading and Managing Globally from IMD and Yale School of Management in 2022.
Kedrion Biopharma
19 followers
Kedrion Biopharma is a biopharmaceutical company that collects and fractionates blood plasma to produce and distribute worldwide plasma-derived therapies for use in treating and preventing rare and serious diseases and conditions. In 2022, Kedrion joined forces with BPL (Bio Products Laboratory). Based in the United Kingdom, BPL has over 60 years of experience in the supply of high-quality plasma-derived medicines to treat rare diseases. Kedrion distributes its products in over 100 countries around the world. We have plants in Italy, Hungary, UK and North America, and plasma collection centers in the US and in the Czech Republic. With these figures we are the world’s 5th top player in the field of plasma-derived products. Our goal is to build a diverse and professional workforce, providing job opportunities for talented external candidates as well as internal employees who aim to grow with us. Because our work includes so many interests and skills – from Research to Sales; Plasma Collection to Production – there are abundant possibilities for learning and growth. Kedrion builds bridges: from donors to patients, from plasma to therapies, from challenge to hope.